Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is progressing its development program for SGX942 (dusquetide), a novel therapeutic targeting oral mucositis, a severe side effect of cancer therapy with no currently approved FDA treatment. The condition, known as severe oral mucositis (SOM), frequently leads to hospitalization, requires opioid pain management, and necessitates feeding tube placement, significantly diminishing patients' quality of life during cancer treatment.
The company is currently analyzing combined phase 2 and phase 3 clinical datasets to inform the design of a second pivotal phase 3 study. This analytical approach aims to optimize trial parameters based on previous outcomes, potentially accelerating the path to regulatory approval. Effective treatment or prevention of oral mucositis is critical for maintaining cancer therapy schedules and ensuring patients can sustain nutrition and comfort throughout their treatment regimens.
Soligenix is also actively seeking potential development partners to advance the SGX942 program. The company's broader pipeline includes multiple therapeutic candidates across its Specialized BioTherapeutics and Public Health Solutions business segments. Additional information about the company's development programs is available at https://www.Soligenix.com.
The advancement of SGX942 represents a significant development in supportive cancer care, addressing a substantial unmet medical need that affects countless patients undergoing radiation and chemotherapy treatments. Successful development of this therapy could transform the standard of care for cancer patients experiencing this debilitating complication.
